Compare · A vs ALMR
A vs ALMR
Side-by-side comparison of Agilent Technologies Inc. (A) and Alamar Biosciences Inc. (ALMR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and ALMR operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A carries a market cap of $41.39B.
- Over the past year, A is up 8.1% and ALMR is up 11.7% - ALMR leads by 3.7 points.
- ALMR has been more active in the news (16 items in the past 4 weeks vs 2 for A).
- A has more recent analyst coverage (25 ratings vs 0 for ALMR).
- Company
- Agilent Technologies Inc.
- Alamar Biosciences Inc.
- Price
- $115.53+1.05%
- $24.80+3.20%
- Market cap
- $41.39B
- -
- 1M return
- +2.27%
- +11.74%
- 1Y return
- +8.07%
- +11.74%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- 2026
- News (4w)
- 2
- 16
- Recent ratings
- 25
- 0
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Latest A
- Agilent Showcases Cancer Research Solutions at AACR 2026
- Amendment: Agilent Technologies Inc. filed SEC Form 8-K: Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits
- Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 4 filed by Henson Meghan
- Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
- Amendment: SEC Form SCHEDULE 13G/A filed by Agilent Technologies Inc.
- Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
- SEC Form 4 filed by Rataj Sue H.
- SEC Form 4 filed by Brawley Otis W
- SEC Form 4 filed by Scangos George A
Latest ALMR
- SEC Form SCHEDULE 13D filed by Alamar Biosciences Inc.
- SEC Form SCHEDULE 13D filed by Alamar Biosciences Inc.
- SEC Form 4 filed by Qiming Corporate Gp Vi, Ltd.
- SEC Form EFFECT filed by Alamar Biosciences Inc.
- SEC Form 4 filed by Illumina Innovation Fund Ii Gp, L.L.C.
- SEC Form 4 filed by Chambers Rebecca
- SEC Form 4 filed by Witney Frank
- SEC Form 4 filed by White Timothy Ogden
- SEC Form 4 filed by Chen Shiping
- SEC Form 4 filed by Luo Yuling